Evotec's partner Exscientia receives first CTA approval for Phase I/II trial of EXS-21546

  • Evotec’s partner Exscientia plc today announced clinical trial application (“CTA”) approval of a Phase I/II trial of EXS-21546, an A2a receptor antagonist, co-invented and developed through a collaboration between Exscientia and Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotecs-partner-exscientia-receives-first-cta-approval-for-phase-iii-trial-of-exs-21546-6237

    Du magst vielleicht auch